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Abstract
Background: In recent decades, asthma‐related quality of life questionnaires have
joined objective clinical indicators as important outcome measures. In this study, we
sought to investigate the predictors of asthma‐related quality of life in a large
cohort of patients recruited from a secondary care center.
Methods:We conducted a cross‐sectional study on asthmatics (N = 1301) recruited
from the Liège University Hospital asthma clinic (Belgium). After performing a
descriptive analysis highlighting the distribution of scores from the Mini Asthma
Quality of Life Questionnaire (Mini AQLQ) and its four dimensions (symptoms,
activity limitation, emotional function, and environmental stimuli), we did multiple
regression analysis to identify the independent predictors of AQLQ.
Results:Multiple regression beta analysis showed that AQLQ and its four dimensions
were primarily associated with asthma control (p < 0.0001 in all instances). Female
gender was associated with a lower score for the AQLQ's activity and environmental
dimensions (p < 0.05 for both), while current smokers had a higher score on the
AQLQ's environmental dimension (p < 0.0001). The burden of asthma treatment was
associated with a lower score for the AQLQ's emotional (p < 0.05) and environmental
(p < 0.05) dimensions. BMI was associated with a lower score in the AQLQ's activity
dimension (p < 0.0001), while the opposite was true for the FeNO test (p < 0.0001).
Sputum neutrophils were inversely related to the score for the AQLQ's symptom
dimension (p < 0.05), whereas post‐bronchodilator FEV1 showed a positive rela-
tionship for that same dimension (p < 0.05).
Conclusion: Asthma control is the main predictor of AQLQ score and impacts all its
dimensions, but demographic, functional, and airway inflammatory parameters may
also influence some dimensions of the AQLQ.
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1 | INTRODUCTION
Asthma is defined by the Global Initiative of Asthma (GINA) as a
heterogeneous disease, usually characterized by chronic airway
inflammation. It is diagnosed by a history of respiratory symptoms
such as wheezing, shortness of breath, chest tightness, and cough
that vary over time and in intensity, together with variable expiratory
airflow limitation.1
This disease is a growing burden in terms of morbidity, health care
costs, and health‐related quality of life (HRQL).2 In recent decades, as a
result of a paradigm shift towards patient‐centered care, subjective
measures of HRQL in asthma have become important outcomes
alongside objective clinical outcomes.3 International asthma treatment
guidelines have therefore evolved to include improvement in patients'
HRQL through long‐term control of the disease, minimizing symptoms,
and improving physical, psychological, and social functioning.4
Unravelling the predictors of asthma‐related quality of life is
important for understanding the disease and its treatment, and
should provide meaningful information about the impact of the dis-
ease and its treatment on patients' perceived health.5
Many previous studies have explored factors associated with
asthma‐relatedquality of life.6 They showed that themain factorswere
asthma control,7‐9 gender,10‐13 age,9,13 body mass index (BMI),12,14
education,9 and sociodemographic parameters.11,13 Some studies have
also shown a weak univariate relationship between HRQL and lung
function as measured by forced expiratory volume in 1 s (FEV1).
13,15
As for the inflammatory component, some studies have explored
the relationship between asthma‐related quality of life and the
fraction of exhaled nitric oxide (FeNO), with contrasting results.16‐18
To the best of our knowledge, no studies have explored the impact of
granulocytic sputum cell count on asthma‐related quality of life,
although airway inflammation is included in the definition of asthma.
In this study we assessed the predictors of asthma‐related quality of
life in a large cohort of asthmatics who were well characterized with
respect to demographic features, lung function, and systemic and
airway inflammatory parameters.
2 | METHODS
2.1 | Study design, setting, and participants
This was a cross‐sectional study on asthma patients recruited from
the Liege University Hospital Asthma Clinic (Belgium) between 2003
and 2019. In accordance with the GINA, the asthma diagnosis was
based on the presence of typical symptoms (wheezing, breathless-
ness, chest tightness, and cough) combined with an FEV1 that
increased at least 12% over baseline and was at least 200 ml after
inhalation of 400 μg salbutamol and/or a provocative concentration
of methacholine causing a 20% drop in FEV1 ≤16 mg/ml. We
excluded patients under the age of 18 years and those not clinically
diagnosed with asthma who failed to meet the reversibility or
bronchial hyperresponsiveness criteria. Then, from the patients with
asthma, we selected those who completed two asthma‐related
patient‐reported outcome measures (PROMs), namely the Asthma
Control Test (ACT)19 and the Mini Asthma Quality of Life Ques-
tionnaire (Mini AQLQ)20 on their first visit to the asthma clinic. The
sample size was 1301 asthmatics (Figure 1).
2.2 | Variables
All the variables used in this study were entered into the asthma
clinic database during routine visits.
2.2.1 | Asthma‐related quality of life (dependent
variable)
Asthma‐related quality of life was measured using the Mini Asthma
Quality of Life Questionnaire (Mini AQLQ). This scientifically‐
validated questionnaire has been translated into more than 20 lan-
guages and is intended for adults with asthma. It includes 15 items
divided into four different dimensions: symptoms (5 items), activity
limitation (4 items), emotional function (3 items) and environmental
stimuli (3 items). The 15 items are scored on a seven‐point Likert
scale; the score for the questionnaire as a whole and for the indi-
vidual dimensions are simply averages of the responses to the
questions within them.20 Seven is the highest score in terms of
asthma‐related quality of life. The minimal clinically important
difference—the smallest difference in a quality of life score that the
patient perceives as clinically important21—is 0.5 for Mini AQLQ.
2.2.2 | Independent variables
Weselected different variables fromour database thatmight influence
asthma‐related quality of life.Wegathered them into twomain groups:
patient demographic characteristics and disease characteristics.
Patient demographic characteristics were age, gender, BMI,
smoking status, age of onset
of asthma, and treatment. Smoking status was divided in three cat-
egories: never‐smoker, ex‐smoker (quit smoking at least 6 months
previously) and current smoker. Treatment was divided in four cat-
egories: (1) no treatment; (2) SABA alone as needed; (3) maintenance
treatment including ICS + LABA and/or LTRA and/or LAMA; (4) any
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maintenance treatment and oral corticosteroid (OCS). Exacerbations
in the year prior to the visit was defined by at least a three‐day
course of OCS in non‐OCS treated patients and a quadrupling in
dose for patients on maintenance OCS.
Disease characteristics were asthma control, atopy, lung function,
and systemic and airway inflammation. Asthma control was assessed
using the Asthma Control Test (ACT), which consists of five questions
related to symptomatology and activity limitation. Each question
contains five items, each scored on a scale from 1 to 5. Studies have
established cutoff scores for asthma that is well‐controlled (ACT ≥
20), not well‐controlled (ACT ≤ 19), and uncontrolled (ACT ≤ 15).19,22
Atopy was defined by one positive IgE test (>0.35 kU/L) to one or
more common aeroallergens (grass pollen, tree pollen, cat, dog, molds,
and house dust mite). Lung function testing was performed by
spirometry (Spiro bank; MIR, Rome, Italy). A post‐bronchodilator
(reversibility) test was done for each patient, irrespective of their
baseline FEV1 and FEV1/forced vital capacity (FVC) ratio, as a stan-
dard procedure. The best of three consecutive spirometry readings
was used, as recommended by the European Respiratory Society.
Patients were administered 400 μg of inhaled salbutamol via a
metered‐dose inhaler (Ventolin) and a spacer (Volumatic), one puff at
a time into the spacer, and spirometry was performed again 15 min
later.23 Patients with baseline FEV1 ≥ 70% predicted were given a
methacholine challenge test, as previously described.23 Using tidal
breathing, the subjects inhaled successive quadrupling methacholine
concentrations from 0.06 mg/ml to 16 mg/ml for one minute each;
FEV1 was measured 30 and 90 s after each concentration. The test
was stopped if FEV1 fell at least 20% from its baseline value. The
PC20Mwas calculated by linear interpolation from the last two points
of the curve. Inflammatory parameters included fractional exhaled
nitric oxide (FeNO), sputum cell counts, blood cell counts, and sys-
temic markers. FeNOwas measured at a flow rate of 50 ml/s (NIOX®;
F I GUR E 1 Flow chart of the patient selection process. ACT, Asthma Control Test; AQLQ, Asthma Quality of Life Questionnaire; PROM,
patient‐reported outcome measure
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Aerocrine, Solna, Sweden). Sputum induction and processing were
performed as previously described.24 The success rate of sputum in-
duction and analysis in our asthma clinic was 78% (1013 of 1301
asthma patients). C‐reactive protein (CRP), fibrinogen, blood eosino-
phils, and neutrophil counts were determined by routine laboratory
analysis at Liège University Hospital.
2.3 | Statistical analysis
The normality of the distribution of the quantitative data was evalu-
ated numerically by comparingmean andmedian and graphically using
a histogram and quantile‐quantile plot. The Shapiro‐Wilk test for
normality was used to complete this assessment. Quantitative vari-
ables were summarized accordingly using median and interquartile
range (P25–P75), while counts and percentages were calculated for
qualitative variables. The number and percentage of missing values
were also reported. The associations between the quantitative vari-
ables and the AQLQ and its subscales (symptom dimension, activity
dimension, emotional dimension, and environmental dimension) were
first determined using the Spearman correlation coefficient. We
further analyzed the determinants of AQLQ and its four subscales by
multiple regression analysis. Based on the skewed and bounded—that
is, values restricted to the interval between 1 and 7 – structure of the
outcome variable, a beta regression model was considered. To do that,
the outcome values were rescaled to the unit interval using the
following transformation y^* = ([y (n‐1)+0.5])/n where n is the
sample size.25 In this study, the best of the several models
fitted was selected using the Akaike information criterion (AIC),
with a lower AIC value indicating a better fit. All statistical
modeling was done using R statistical software at a significance
level of 0.05.
2.4 | Ethics
This study was approved by the Liège University Hospital ethics
committee. Signed informed consent was obtained from patients as
soon as they entered the asthma clinic. They agreed to allow their
clinical data and the health outcomes they reported in the routine
setting to be used for research purposes.
3 | RESULTS
3.1 | Characteristics of the study population
The demographic characteristics of the study population are pre-
sented in Table 1. The majority of subjects were female (60%). Never‐
smokers represented 54% of our population, while ex‐smokers and
current smokers accounted for 26% and 20% of the population,
respectively. Atopy was found in a slim majority of patients (54%).
The median BMI was 26 kg/m2, with an interquartile range (IQR)
from 23–30, meaning that 25% of our population was obese. The vast
majority of asthma patients were receiving medical treatment for
asthma at the time of the visit (84%); the types of treatment are
detailed in Table 1. Thirty‐seven percent of patients (440/1195) re-
ported an exacerbation in the 12 months prior to the visit.
TAB L E 1 Demographic characteristics
Variable Median (IQR)/Percentage (n) Percentage (number) of missing values
Age (years) 51 (37–62) 0% (0)
Gender (male) 40% (523) 0% (0)





22 (10–50) 21% (270)
BMI (kg/m2) 26 (23–30) 0.08% (1)
Atopy (yes) 54% (648) 9% (113)
Exacerbations (yes) 37% (440) 8% (106)
Any asthma treatment (yes) 84% (1095) 0.2% (2)
No treatment 15.7% (204) 0% (0)
SABA alone as needed 22.4% (291) 0% (0)
Maintenance treatment (ICS/LABA and/or LTRA and/or LAMA) 51.6% (671) 0% (0)
Any maintenance treatment + OCS 10.2% (133) 0.2% (2)
Abbreviations: BMI, Body Mass Index; ICS, Inhaled corticosteroids; IQR, interquartile range; LABA, long‐acting beta agonists; LAMA, long‐acting
antimuscarinics; LTRA, leukotriene receptor antagonists; n, number of patients; OCS, oral corticosteroids; SABA, short acting beta agonists.
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The median AQLQ score was 4.53 with a non‐Gaussian distribu-
tion, as shown in Figure 2. Likewise, the distributions of the different
AQLQdimensionswerenonparametric (Figure2). Asthmacontrol, lung
function, and inflammatory characteristics are shown in Table 2. For
asthma control, the median ACT was 15 with an IQR of 11–20, indi-
cating that 25% of the cohort had well‐controlled asthma (ACT ≥ 20).
F I GUR E 2 Distribution of the global AQLQ score and its four dimensions for the entire cohort (N = 1301). AQLQ, Asthma Quality of Life
Questionnaire; IQR, interquartile range; SEM, standard error of the mean
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3.2 | Correlation between asthma‐related quality of
life and demographic and disease characteristics
The correlation between demographic and clinical parameters and
the AQLQ variable and its four subscales are reported in Table 3.
ACT was strongly positively correlated with global AQLQ score
(r = 0.81) and its four subscales. To a lesser extent, FEV1 pre (%),
FEV1 post (%), FVC pre (%), and FVC post (%) were positively
correlated with global AQLQ score and its four subscales. BMI was
weakly and inversely correlated with global AQLQ score and its
symptoms and activity subscales. All of the inflammatory parameters
were inversely correlated with global AQLQ score except for FeNO
and total serum IgE, which displayed no correlation. Those two in-
flammatory parameters did, however, show a significant relationship
with two of the subscales: FeNO was positively associated with the
activity dimension and total serum IgE was negatively associated
with the emotional dimension. Among the inflammatory parameters,
blood neutrophils exhibited the strongest relationships.
3.3 | Multivariate beta regression
The results of multivariate beta regression analysis are presented in
Table 4. ACT was the only determinant displaying significant associa-
tion with global AQLQ (p < 0.0001) and its four subscales (p < 0.0001).
None of the other independent variables was associated with global
AQLQ. Gender had an influence on the activity and environmental
domains; females had lower asthma‐related quality of life scores in the
activity (p = 0.047) and environmental (p = 0.013) domains than did
males. Likewise, treatment had a significant association with the
emotional and environmental subscale scores. That is, patients being
treated with ICS + LABA and/or LTRA and/or LAMA and patients
receiving any maintenance treatment + OCS had lower scores on the
asthma‐related quality of life emotional and environmental subscales
than did untreated patients (p < 0.05). Smokers had higher asthma‐
related quality of life scores for the environmental subscale than did
non‐smoking patients (p < 0.0001). BMI was inversely associated with
the activity subscale (p < 0.0001), while FeNO (ppb) was positively
associated with this subscale (p < 0.0001). Post‐bronchodilation FVC
and sputum neutrophils were inversely associated with the symptom
dimension of AQLQ (p < 0.05), while the reverse was found for post‐
bronchodilation FEV1 (p < 0.05).
3.4 | Relationship between FeNO and the AQLQ
activity dimension
When we applied the FeNO value categories recommended by the
American Thoracic Society clinical practice guidelines, we found that
the group with low FeNO values (<25 ppb) had the poorest reported
quality of life (Figure 3, upper panel). There was a gradual increase in
the proportion of patients reporting high AQLQ (≥6), from 23% in the
TAB L E 2 Asthma control, lung function, and inflammatory characteristics
Variable Median (IQR)/Percentage (frequency) Percentage (number) of missing value
ACT 15 (11.0–20.0) 0% (0)
FEV1 pre (% pred.) 86 (73.0–99.0) 0.23% (3)
FEV1 post (% pred.) 91 (78.5–104.0) 0.61% (8)
FVC pre (% pred.) 95 (82.0–106.0) 0.15% (2)
FVC post (% pred.) 97 (85.0–108.0) 0.69% (9)
FEV1/FVC pre (%) 76 (69.0–82.0) 0.15% (2)
FEV1/FVC post (%) 79 (72.0–84.0) 0.61% (8)
Reversibility (%) 5.0 (1.0–11.0) 0.5% (7)
PC20M (mg/ml) 3.5 (0.92–14.21) 40.5% (527)
FeNO (ppb) 22 (13.0–42.0) 2.07% (27)
Sputum neutrophils (103/g) 764 (272–2662.5) 22.14% (288)
Sputum eosinophils (103/g) 27 (1.12–192.66) 22.14% (288)
Blood neutrophils (1/μl) 3966 (3077–5254) 2.0% (26)
Blood eosinophils (1/μl) 171 (98.0–298.0) 2.0% (26)
Total serum IgE (kU/L) 98 (30.0–291.0) 4.15% (54)
Fibrinogen (g/L) 3.25 (2.75–3.78) 5.69% (74)
CRP (mg/L) 2.15 (0.9–5.01) 4.84% (63)
Abbreviations: ACT, Asthma Control Test; BMI, Body Mass Index; CRP, C‐reactive protein; FENO, fraction of exhaled nitric oxide; FEV, forced
expiratory volume in 1 s; FVC, forced vital capacity; IQR, interquartile range; n, number of patients; PC20M, provocative methacholine concentration
causing a fall in FEV1 of 20%.
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low FeNO group to 31% in the high FeNO group (OR = 0.66; 95 CI
from 0.48 to 0.91; p < 0,05) (Figure 3, lower panel).
4 | DISCUSSION
In this large cross‐sectional study, we identified several predictors of
asthma‐relatedqualityof lifeand/or its fourdimensionsasmeasuredby
the AQLQ. First, our results show that ACT is the factor most signifi-
cantly associatedwithglobalAQLQand its fourdimensions (symptoms,
activity limitation, emotional function, and environmental stimuli).
Second, our results show that some demographic characteristics—
gender, BMI, smoking status, and treatment—are predictors of
certain dimensions of asthma‐related quality of life. Third, while
cellular inflammatory and lung function parameters are correlated to
theglobalAQLQ, the correlationno longerholds trueaftermultivariate
analysis. Finally, and this is themost original finding of our study, FeNO
appears to be positively associated with the activity dimension.
4.1 | Relationship between asthma‐related quality
of life and asthma control
The level of asthma control as assessed by ACT was identified as the
leading predictor of asthma‐related quality of life as measured by the
AQLQ. Indeed, it was the only factor strongly associated with global
AQLQ and all of the AQLQ dimensions. These results are in line with
previous studies indicating that asthma control had a strong influ-
ence on HRQL.7‐9,26‐29 Chen et al.8 using a multivariate analysis in a
large cohort, found an inverse relationship between asthma control
(measured by Asthma Therapy Assessment Questionnaire) and both
asthma‐specific HRQL, measured by the Mini AQLQ, and generic
HRQL, measured by EuroQol 5‐D. Likewise, Pereira et al. (2011)26
reported an inverse relationship between asthma control (measured
by ACT) and asthma‐specific HRQL as measured by the Saint Geor-
ges's Respiratory Questionnaire (SGRQ), but that study investigated
only a limited number of patients. The strong relationship between
ACT and AQLQ in our study (rs = 0.81) can be explained, in part, by
TAB L E 3 Correlation between AQLQ scores and demographic and disease characteristics
Global AQLQ Symptom dimension Activity dimension Emotional dimension Environmental dimension
Correlation p‐value Correlation p‐value Correlation p‐value Correlation p‐value Correlation p‐value
ACT 0.81 <0.0001 0.79 <0.0001 0.76 <0.0001 0.71 <0.0001 0.48 <0.0001
Age (years) −0.01 0.84 0.04 0.12 −0.12 <0.0001 0.01 0.64 0.04 0.11
Age of onset of
asthma (years)
0.06 0.04 0.04 0.26 −0.03 0.31 0.10 0.001 0.14 <0.0001
BMI (kg/m2) −0.12 <0.0001 −0.10 0.0003 −0.21 <0.0001 −0.07 0.009 −0.03 0.26
FEV1 pre (% pred.) 0.31 <0.0001 0.26 <0.0001 0.34 <0.0001 0.29 <0.0001 0.15 <0.0001
FEV1 post (% pred.) 0.31 <0.0001 0.26 <0.0001 0.34 <0.0001 0.28 <0.0001 0.15 <0.0001
FVC pre (% pred.) 0.28 <0.0001 0.22 <0.0001 0.34 <0.0001 0.23 <0.0001 0.13 <0.0001
FVC post (% pred.) 0.24 <0.0001 0.18 <0.0001 0.30 <0.0001 0.19 <0.0001 0.12 <0.0001
FEV1/FVC pre (%) 0.12 <0.0001 0.10 <0.0001 0.11 <0.0001 0.16 <0.0001 0.02 0.51
FEV1/FVC post (%) 0.14 <0.0001 0.13 <0.0001 0.15 <0.0001 0.17 <0.0001 0.03 0.36
FeNO (ppb) 0.04 0.13 0.03 0.25 0.09 0.0007 −0.02 0.47 −0.01 0.84
Fibrinogen (g/L) −0.14 <0.0001 −0.12 <0.0001 −0.19 <0.0001 −0.08 0.003 −0.06 0.04
CRP (mg/L) −0.10 0.0004 −0.11 <0.0001 −0.14 <0.0001 −0.04 0.17 −0.03 0.22
Total serum IgE
(kU/L)
0.00 0.98 0.01 0.65 0.03 0.24 −0.08 0.006 0.00 0.93
Sputum neutrophils
(103/g)
−0.06 0.04 −0.06 0.07 −0.08 0.01 −0.03 0.37 −0.05 0.14
Sputum eosinophils
(103/g)
−0.09 0.006 −0.09 0.004 −0.06 0.08 −0.10 0.002 −0.06 0.05
Blood neutrophils
(1/μl)
−0.20 <0.0001 −0.19 <0.0001 −0.22 <0.0001 −0.17 <0.0001 −0.07 0.01
Blood eosinophils
(1/μl)
−0.08 0.004 −0.08 0.007 −0.07 0.01 −0.10 <0.0001 −0.04 0.12
Note: Correlation was calculated using the Spearman coefficient.
Abbreviations: ACT, Asthma Control Test; AOLQ, Asthma Quality of Life Questionnaire; BMI, Body Mass Index; CRP, C‐reactive protein; FENO, fraction
of exhaled nitric oxide; FEV, forced expiratory volume in 1 s; FVC, forced vital capacity.
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the fact that two of the AQLQ's dimensions (activity limitation and
symptoms) are also found in the ACT. The overlap of common do-
mains is likely to strengthen the relationship between the two
questionnaires.28
4.2 | Relationship between asthma‐related quality
of life and demographics
In our study, although there was no difference in global AQLQ,
women reported poorer asthma‐related quality of life in the activity
limitation and environmental stimuli domains. Our finding of a sig-


























































































































































































































































































































































































































































































































































F I GUR E 3 Comparison of the asthma‐related quality of life
(AQLQ) activity dimension between patients grouped according to
the American Thoracic Society classification for FeNO values
(upper panel) and proportion of patients with high AQLQ
(AQLQ ≥ 6) in the activity dimension (lower panel). Results are
expressed as mean ± standard error of the mean. FeNO < 25 ppb
group (N = 698), FeNO 25–50 ppb group (N = 329), and FeNO > 50
ppb group (N = 252) (upper panel)
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activity limitation and environmental stimuli is perfectly in line with
the study by Naleway et al.10 Other studies reported that women
with asthma experienced a lower HRQL11,13,30,31 Some authors30,32
believe that the relationship between gender and asthma‐related
quality of life is related to the higher prevalence of anxiety and
depression among women compared to men. While our study found
no gender differences in the AQLQ's emotional dimension, that
dimension does not take anxiety and depression into account.
An earlier study reported that asthmatic smokers had a lower
generic HRQL.11 We were unable to confirm this finding when
focusing solely on asthma‐related quality of life. On the contrary, in
the present study smokers had a higher asthma‐related quality of life
in the environmental domain than did non‐smokers. Though this
seems surprising, it can be explained by the composition and
formulation of the AQLQ's environmental questions. Of the three
questions that make up the AQLQ's environmental domain, one asks
whether the patient has been bothered by cigarette smoke. It is very
likely that most smokers responded “rarely or never” to this question.
It is worth noting, moreover, that the relationship between smoking
and asthma‐related quality of life is different than that between
smoking and asthma control, where smoking has a clear detrimental
effect on the level of control.33 This illustrates the fact that although
asthma control and asthma‐related quality of life are strongly related,
they reflect different dimensions of the disease.
Obesity is a major comorbidity in asthma, affecting up to 25%–
50% of severe asthmatics, depending on the country.34 In our study,
BMIwas negatively, thoughweakly, associatedwith the AQLQ activity
limitation subscore. This means that the higher the asthma patient's
BMI, the poorer his or her asthma‐related quality of life in the activity
dimension. This finding is consistent with another study by Lavoie
et al.14 and is readily understandable given the burden obesity places
on everyday movement. It also demonstrates the importance of
considering comorbidities when assessing asthmatics' quality of life.
Our study showed no association between either atopy—which
was present in more than half of the asthma cohort—or total serum
IgE and global asthma‐related quality of life or any of its subscales.We
therefore could not confirm that non‐atopic asthma might have a
greater negative impact of asthma‐related quality of life, as found in a
previous study.35 In that study, over 70% of the cohort were atopic
patients whowere younger and had less severe disease; only half were
being treated with ICS and the average FEV1 was greater than 90%
predicted. In our cohort, atopic patients had an average baseline FEV1
of 84% predicted, and 59% were being treated with ICS/LABA (data
not shown). We therefore believe that our population of atopic asth-
matics had more severe disease than that of Ek et al.35 Our data
support the hypothesis that atopy is a prominent trait associated with
asthma, but is not a determinant factor in worsening or improving
quality of life.
Our data indicate that treatment burden has an impact on the
emotional and environmental dimensions of asthma‐related quality
of life. Unlike patients who receive SABA alone as needed, the pa-
tients receiving maintenance treatment (ICS/LABA and/or LTRA and/
or LAMA)—and those receiving OCS, in particular—showed
diminished quality of life. Presumably, the intensity of the pharma-
cological treatment makes the patients more aware of their fragility
in anxiety‐producing and stressful situations.
4.3 | Relationship between asthma‐related quality
of life and lung function
Confirming previous results,8,13,15 we found a low inverse relation-
ship between FEV1 and global AQLQ, supporting the idea that airflow
limitation results in impaired quality of life. This relationship
remained significant after multiple regression analysis, but only for
the symptom dimension of the AQLQ. This supports the hypothesis
that FEV1 contributes to the scoring of the symptom dimension of
asthma‐related quality of life.
4.4 | Relationship between asthma‐related quality
of life and inflammation
Airway inflammation is an essential component of asthma. To the best
of our knowledge, no studies have looked at the direct relationship
between asthma‐related quality of life and airway or systemic
inflammation. Thus, one unique aspect of our study was its exploration
of the link between asthma‐related quality of life and airway inflam-
mation. The magnitude of neutrophilic and eosinophilic inflammation
both at the systemic and airway level correlates inversely with global
AQLQ score; the more eosinophils and/or neutrophils in the sputum
and blood, the poorer the asthma‐related quality of life. Only the as-
sociation between sputum neutrophils and the symptom dimension of
AQLQ remained significant after multiple regression analysis. The fact
that the relationship between sputum eosinophils and AQLQ dis-
appeared aftermultiple regression analysis suggests that the observed
correlation between sputum eosinophils and AQLQ was mediated
through poor asthma control. This is consistentwith previous studies—
both cross‐sectional and longitudinal—that have shown that sputum
eosinophils are independent determinants of the fluctuation in asthma
control.33,36,37
Finally, our multivariate analysis yielded a surprising and inter-
esting result regarding FeNO. It showed that FeNO was positively
associated with the activity dimension of asthma‐related quality of
life. High FeNO has traditionally been seen as a bad outcome
reflecting intense eosinophilic inflammation.38 In addition, Roberts
et al.17 focusing on teenagers with allergic asthma, demonstrated
that quality of life declines when FeNO increases as a result of pollen
allergen exposure. In contrast, Ehrs et al.16 found no relationship
between FeNO and AQLQ in a population of mild, untreated asth-
matics. Caminati et al.18 showed that AQLQ scores in patients with
severe allergic asthma were lower in patients with FeNO ≥30 ppb
than in patients with FeNO <30 ppb. None of these studies used
multiple regression analysis, and FeNO may be affected by other
factors likely to impact its effect on AQLQ in a univariate analysis,
such as airway eosinophilia. We therefore believe that our statistical
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methods better reflect the true association between FeNO and
quality of life. The reason why FeNO might positively affect the ac-
tivity dimension of quality of life remains to be investigated, but it is
worth noting that NO is a recognized mediator of vasodilation,39
which is a physiological process of utmost importance in physical
activity. While FeNO is usually considered to be the consequence of
activation of inducible NO synthase due to local inflammation,40 we
cannot rule out the possibility that part of FeNO actually reflects an
inherited propensity of the body to synthesize NO.
4.5 | Limitations of the study
The strength of this study lies in the size of the cohort, the use of
validated PROMs (Mini AQLQ and ACT), and the inclusion of clini-
cally well‐characterized asthma patients; our study does, however,
have several limitations. As this was a cross‐sectional study, the
cause and effect of these associations cannot be determined. Another
limitation is the lack of sociodemographic data such as the occupa-
tion or education level, which are likely to influence asthma‐related
quality of life.3,8 The strength of the relationship between asthma
control and asthma‐related quality of life might have been weaker, if
asthma‐related quality of life had been assessed by a different
questionnaire that considered other quality‐of‐life dimensions.41
Finally, our analysis did not include several comorbidities—such as
rhinosinusitis or gastroesophageal reflux—known to impact asthma
patients' quality of life.35,42,43
5 | CONCLUSION
Asthma control is the main predictor of asthma‐related quality of life
and impacts all of its dimensions, but demographic, functional, and
airway inflammatory parameters may also influence some aspects of
asthma‐related quality of life. Among the airway inflammatory pa-
rameters, FeNOemerged as the inflammatory factormost significantly
associated with AQLQ, and surprisingly the relationship between
FENO and the activity dimension was positive. Whatever the reason
for this, our study shows that considering patient‐reported outcomes
might refine clinicians' views on an objective physiological parameter.
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